logo

Tag

Bulgaria

Can the new rules limit competition in the sector?

April 1, 2019 amendments to Regulation 10 concerning pharmaceutical product reimbursement were introduced. Can the new rules limit competition in the sector? New rules effective April 1, 2019, allow NHIF to charge pharmaceutical companies if their sales exceed sales (value) from previous periods. The sales numbers will be now monitored every quarter. As introduced, the current rules are expected to bear future revisi
Read More

Understand Changes in Drug Pricing in Bulgaria

On April 1st, 2019, few regulation on drug pricing and inclusion in the positive drug list were updated and in force. Here is a brief summary of the rules that impact directly drug prices in Bulgaria
Read More
Pharmaceutical Manufacturing Facilities in Bulgaria

Pharmaceutical Manufacturing Facilities in Bulgaria

The map of the Pharmaceutical Manufacturing Facilities in Bulgaria Project Work. This is an open source data which you can find on Google Maps. The current map of the Pharmaceutical Manufacturing Facilities in Bulgaria is under development and updates frequently. Note, that names for a few of the facilities may be changed due to the change in ownership (e.g. Actavis facility in Dupnitza is now part of TEVA; Actavis´
Read More
Parallel Trade of Pharmaceuticals

Restrictions on parallel trade in pharmaceuticals

The article is only available in Bulgarian, read the full article via ResearchGate web site.
Read More
EPR Overview Bulgaria

Brief EPR overview & prognosis, the Bulgaria’s perspective

The debate over fare medicinal products pricing is one of the most contentious issues that emerges again within the EU countries. External price referencing (EPR) is used by many EU member states (and others) for the last years as a measure and tool to control marketed medicinal products’ prices. Authors’ strong believe is that although EPR tool embraces viable and progressive concepts is highly liberalized in its ap
Read More